# A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Source: https://onco.cc/trials/nct07276399/  
OnCo record `nct07276399` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Amivantamab, Pembrolizumab, Carboplatin and Cisplatin in head and neck squamous cell carcinoma, run by Janssen Research & Development, LLC, now recruiting.

## Summary

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer is a phase 3 interventional study registered as NCT07276399 by Janssen Research & Development, LLC, with 500 participants planned, started 2025-12-03 and due to reach its primary completion in 2029-06-18. Interventions recorded: Amivantamab, Pembrolizumab, Carboplatin, 5-Flurouracil and Cisplatin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07276399
- Phase: 3
- Setting: A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 500

## Sources

- ClinicalTrials.gov NCT07276399: https://clinicaltrials.gov/study/NCT07276399

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Amivantamab](https://onco.cc/drugs/amivantamab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct07276399.json